-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $259

Benzinga·10/08/2026 14:54:15
Listen to the news
RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $251 to $259.